About Sapphire Therapeutics
Sapphire Therapeutics is a Healthcare company based in Iselin (United States) founded in 2008, and was acquired by Helsinn in January 2009. Small molecule drugs are developed for metabolic and oncologic disorders. Its focus areas include Diversified Pharmaceuticals.
Company details
Sapphire Therapeutics was founded in 2008 and is headquartered in Iselin, United States. Focus is placed on the development of small molecule drugs targeting metabolic and oncologic disorders within the biotechnology sector. The pipeline features anamorelin in phase 2 trials for cancer cachexia, ipamorelin in phase 2 for postoperative ileus, and ST-114 in phase 1 for opioid-induced bowel dysfunction. Operations center on advancing these therapeutic candidates through clinical stages.
- Headquarters Iselin, United States
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website sapphirethera.com
- Social LinkedIn
- Acquired by Helsinn (Jan 2009)
Investors in Sapphire Therapeutics
Sapphire Therapeutics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Helsinn.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Oncology therapeutics are developed, manufactured, and commercialized by Helsinn. | 1976 | helsinn.com | Lugano, Switzerland |
Investor details for Sapphire Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Sapphire Therapeutics
2 dated milestones of Sapphire Therapeutics across 1 years, from founding to its latest funding, stage changes and deals.
- Founded Sapphire Therapeutics is founded.
- Exit Acquired by Helsinn.
Top companies in Pharmaceuticals & Distribution
3 companies that operate in the same segment as Sapphire Therapeutics (Pharmaceuticals & Distribution) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | USD 33.23 B | 28,000 | ||
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | USD 61.16 B | 55,000 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Sapphire Therapeutics
Complete news archive for Sapphire Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sapphire Therapeutics
Sapphire Therapeutics was founded in 2008.
Sapphire Therapeutics is headquartered in Iselin, United States. It is registered at Iselin, New Jersey, United States.
Sapphire Therapeutics was founded in 2008 and is headquartered in Iselin, United States. Focus is placed on the development of small molecule drugs targeting metabolic and oncologic disorders within the biotechnology sector. The pipeline features anamorelin in phase 2 trials for cancer cachexia, ipamorelin in phase 2 for postoperative ileus, and ST-114 in phase 1 for opioid-induced bowel dysfunction. Operations center on advancing these therapeutic candidates through clinical stages.
Sapphire Therapeutics has 1 investor. Key investors include Helsinn.
Yes. Sapphire Therapeutics was acquired by Helsinn in January 2009.